Evidence syntheses — page 3
140 structured review questions, each with a registered PICO frame, a reproduced search, an included-studies table, a summary of findings and an amendment log.
Reviews
-
In the population defined for obesity and overweight in adults, what is the effect of Semaglutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High22 Oct 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Semaglutide compared with its comparator?
High08 May 2025 -
In the population defined for type 2 diabetes mellitus, is the effect of Dulaglutide maintained across the full duration of the contributing trials?
High12 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Dulaglutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High14 Apr 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Dulaglutide compared with its comparator?
High21 May 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Semaglutide maintained across the full duration of the contributing trials?
High18 Feb 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Semaglutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High04 Oct 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Semaglutide compared with its comparator?
High18 Jun 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Tirzepatide maintained across the full duration of the contributing trials?
High16 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Tirzepatide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High02 Jun 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with its comparator?
High09 Oct 2025 -
In the population defined for type 2 diabetes mellitus, is the effect of Exenatide maintained across the full duration of the contributing trials?
High27 Feb 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Exenatide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High28 Jul 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Exenatide compared with its comparator?
High31 Jan 2025 -
In the population defined for obesity and overweight in adults, is the effect of Retatrutide maintained across the full duration of the contributing trials?
Moderate16 Nov 2025 -
In the population defined for obesity and overweight in adults, what is the effect of Retatrutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate17 May 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Retatrutide compared with its comparator?
Moderate10 Mar 2025 -
In the population defined for obesity and overweight in adults, is the effect of CagriSema (cagrilintide with semaglutide) maintained across the full duration of the contributing trials?
Moderate13 Mar 2026 -
In the population defined for obesity and overweight in adults, what is the effect of CagriSema (cagrilintide with semaglutide) compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate17 Oct 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with CagriSema (cagrilintide with semaglutide) compared with its comparator?
Moderate13 Jan 2026
page 3 of 7